MannKind Says FDA Reviewing Inhaled Insulin
Stock quotes in this article:
MNKD
VALENCIA, Calif. (AP) — MannKind Corp. said Monday the Food and Drug Administration will review the biotechnology company's application for its experimental inhaled insulin Afresa.
The company is seeking approval for the drug's use in Type 1 or Type 2 diabetics to control high blood sugar levels. MannKind is developing drugs that can be inhaled and absorbed more easily with a technology called Technosphere. Shares of MannKind rose 81 cents, or 13.9 percent, to $6.64 in midday trading. The stock has traded between $2 and $7.50 over the past 52 weeks.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.00 | 1,107.93 | 2,201.05 | 36.03 |
Oil *
72.08
|
|
DOWN
49.05
|
DOWN
6.18
|
DOWN
11.05
|
UP
0.57
|
10 Yr
3.60%
SPDR Gold
110.21
|
|
-0.47%
|
-0.55%
|
-0.50%
|
+1.61%
|
Data delayed 20 minutes |
